Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4+ T cell receptor (TCR) recognizing influenza hemagglutinin (HA)-derived peptides is a specialized antigen receptor found on the surface of helper T lymphocytes. These receptors specifically identify and bind to peptide fragments of the influenza HA protein, such as the immunodominant HA306-318 epitope, when they are presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (PubMed: 25135834). This binding event triggers a signaling cascade through the CD3 complex, leading to T cell activation, proliferation, and the secretion of cytokines like IL-2 and IFN-gamma (Janeway's Immunobiology, 9th Ed). These activated CD4+ T cells play a pivotal role in the immune response by providing essential "help" to B cells for the production of high-affinity neutralizing antibodies and by supporting the generation of memory CD8+ T cells (PubMed: 21844396). In clinical practice, these TCRs are the primary targets of influenza vaccines, which aim to expand the population of HA-specific memory T cells to provide protection against subsequent viral challenges (PubMed: 24037093). However, challenges such as "original antigenic sin" and the high mutation rate of the HA protein can limit the effectiveness of these responses, necessitating the development of vaccines that target more conserved HA epitopes (PubMed: 29305462). Furthermore, cross-reactivity of these TCRs with self-antigens has been implicated in rare adverse events, such as the association between certain flu vaccines and narcolepsy (PubMed: 23520073). Understanding the specificity and diversity of these TCRs is essential for developing universal influenza vaccines and monitoring immune correlates of protection.
Recognition of influenza hemagglutinin peptides presented by MHC class II molecules, triggering intracellular signaling through the CD3 complex to activate helper T cell functions.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4+ T cell receptor recognizing influenza hemagglutinin-derived peptides (HA-specific CD4+ TCR).